| ￥5800 | |
| Z04587 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per ug by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized Human uPAR, hFc Tag at 1μg/ml (100μl/well) on the plate can bind PLAU/uPA (active form)[Biotin], His & Avi, Human. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 49.3 kDa | ||||||
| Apparent Molecular Weight | Due to protein lysis and glycosylation, the protein migrates to 24-26 kDa(long chain A), 35-38 kDa(chain B) and 52-60 kDa(long chain A&chain B) based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC. |
| Synonyms | PLAU; Urokinase; ATF; UPA; URK; u-PA; BDPLT5; QPD |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
